The effect of tamoxifen on the genital tract

Cancer Imaging

Volumn 8, Issue 1, 2008, Pages 135-145

  Polin, Sandra A ^a   Ascher, Susan M ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Adenomyosis; Endometrial cystic atrophy; Endometrial hyperplasia; Endometrial polyp; Hysterosonography; MRI; Ultrasound

Indexed keywords

ESTRADIOL VALERATE; GADOLINIUM; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADENOMYOSIS; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CHEMOPROPHYLAXIS; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOPPLER ECHOGRAPHY; DRUG MECHANISM; DYSPAREUNIA; ECHOGRAPHY; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ESTROGEN SYNTHESIS; FEMALE GENITAL SYSTEM; HIGH RISK PATIENT; HUMAN; HYSTEROSCOPY; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LEIOMYOMA; MALIGNANT TRANSFORMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY; OVULATION; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; UTERINE CERVIX; UTERUS MYOMA; UTERUS SARCOMA; VAGINA; VAGINAL DRYNESS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CERVIX UTERI; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOSONOGRAPHY; FEMALE; FEMALE UROGENITAL DISEASES; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; OVARY; RISK ASSESSMENT; TAMOXIFEN; VAGINA;

EID: 46649093380     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2008.0020     Document Type: Review

References (95)

1. Machado F, Rodriguez JR, Leon JP, Parrilla JJ, Abad L. Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature. Eur J Gynaecol Oncol 2005; 26: 257-65.
2. Neven P, Vernaeve H. Guidelines for monitoring patients taking tamoxifen treatment. Drug Saf 2000; 22: 1-11.
3. ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. Obstet Gynecol 2006; 107: 1475-8.
4. Althuis MD, Sexton M, Langenberg P, et al. Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community based study. Cancer 2000; 89: 800-10.
5. Varras M, Polyzos D, Akrivis C. Effects of tamoxifen on the human female genital tract: review of the literature. Eur J Gynaecol Oncol 2003; 24: 258-68.
6. Neven P, Vergote I. Should tamoxifen users be screened for endometrial lesions? Lancet 1998; 351: 155-7.
7. Cohen I, Altaras MM, Shapira J, Tepper R, Beyth Y. Postmenopausal tamoxifen treatment and endometrial pathology. Obstet Gynecol Surv 1994; 49: 823-9.
8. Cohen I, Beyth Y, Tepper R, et al. Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: a new entity? Gynecol Oncol 1995; 58: 86-91.
9. Ugwumadu AH, Bower D, Ho PK. Tamoxifen induced adenomyosis and adenomyomatous endometrial polyp. Br J Obstet Gynaecol 1993; 100: 386-8.
10. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993; 81: 660-4.
11. Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 1997; 66: 233-7.
12. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994; 343: 1318-21.
13. Barakat RR. Tamoxifen and endometrial neoplasia. Clin Obstet Gynecol 1996; 39: 629-40.
14. Schlesinger C, Kamoi S, Ascher SM, Kendell M, Lage JM, Silverberg SG. Endometrial polyps: a comparison study of patients receiving tamoxifen with two control groups. Int J Gynecol Pathol 1998; 17: 302-11.
15. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994; 47: 827-33.
16. Ascher SM, Imaoka I, Lage JM. Tamoxifen-induced uterine abnormalities: the role of imaging. Radiology 2000; 214: 29-38.
17. Cohen I, Bernheim J, Azaria R, Tepper R, Sharony R, Beyth Y. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 1999; 75: 136-41.
18. Gal D, Kopel S, Bashevkin M, Lebowicz J, Lev R, Tancer ML. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer - preliminary report. Gynecol Oncol 1991; 42: 120-3.
19. Berliere M, Charles A, Galant C, Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 1998; 91: 40-4.
20. Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 1992; 79: 111-6.
21. Karlsson B, Granberg S, Wikland M, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding - a Nordic multicenter study. Am J Obstet Gynecol 1995; 172: 1488-94.
22. Kurman RJ NH. Blausteins's pathology of the female genital tract. Endometrial hyperplasia and related cellular changes. New York: Springer-Verlag, 1994: 411-437.
23. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609-18.
24. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-37.
25. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-88.
26. van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343: 448-52.
27. Uziely B, Lewin A, Brufman G, Dorembus D, Mor-Yosef S. The effect of tamoxifen on the endometrium. Breast Cancer Res Treat 1993; 26: 101-5.
28. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991; 83: 1013-7.
29. Tamoxifen for early breast cancer: an overview of the randomised trials.Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351: 1451-67.
30. Mignotte H, Lasset C, Bonadona V, et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French caso-control study. Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Int J Cancer 1998; 76: 325-30.
31. Peters-Engl C, Frank W, Danmayr E, Friedl HP, Leodolter S, Medl M. Association between endometrial cancer and tamoxifen treatment of breast cancer. Breast Cancer Res Treat 1999; 54: 255-60.
32. Barakat RR, Gilewski TA, Almadrones L, et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol 2000; 18: 3459-63.
33. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993; 11: 485-90.
34. Wilder JL, Shajahan S, Khattar NH, et al. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study. Gynecol Oncol 2004; 92: 553-8.
35. Narod SA, Pal T, Graham T, Mitchell M, Fyles A. Tamoxifen and risk of endometrial cancer. Lancet 2001; 357: 65-6; author reply 67.
36. Lasset C, Bonadona V, Mignotte H, Bremond A. Tamoxifen and risk of endometrial cancer. Lancet 2001; 357: 66-7.
37. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000; 356: 881-7.
38. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004; 94: 256-66.
39. Deligdisch L, Kalir T, Cohen CJ, de Latour M, Le Bouedec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 2000; 78: 181-6.
40. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 1998; 16: 2018-24.
41. Senkus-Konefka E, Konefka T, Jassem J. The effects of tamoxifen on the female genital tract. Cancer Treat Rev 2004; 30: 291-301.
42. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001; 97: 855-66.
43. McGonigle KF, Shaw SL, Vasilev SA, Odom-Maryon T, Roy S, Simpson JF. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 1998; 178: 1145-50.
44. Neven P, De Muylder X, Van Belle Y, Van Hooff I, Vanderick G. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet 1998; 351: 36.
45. Gompel C SS. Pathology in gynecology and obstetrics. In: Gompel C SS, editor. The corpus uteri. 4th ed. Philadelphia: Lippincott; 1994, p. 163-283.
46. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994; 170: 447-51.
47. Achiron R, Lipitz S, Sivan E, Goldenberg M, Mashiach S. Sonohysterography for ultrasonographic evaluation of tamoxifen-associated cystic thickened endometrium. J Ultrasound Med 1995; 14: 685-8.
48. Dilts Jr PV, Hopkins MP, Chang AE, Cody RL. Rapid Gynecol growth of leiomyoma in patient receiving tamoxifen. Am J Obstet 1992; 166: 167-8.
49. Lumsden MA, West CP, Hillier H, Baird DT. Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin) - lack of shrinkage of uterine fibroids. Fertil Steril 1989; 52: 924-9.
50. Klopper A, Hall M. New synthetic agent for the induction of ovulation: preliminary trials in women. BMJ 1971; 1: 152-4.
51. Cohen I, Rosen DJ, Altaras M, Beyth Y, Shapira J, Yigael D. Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth. Br J Cancer 1994; 69: 620-1.
52. Ismail SM. Gynaecological effects of tamoxifen. J Clin Pathol 1999; 52: 83-8.
53. Cook LS, Weiss NS, Schwartz SM, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 1995; 87: 1359-64.
54. Lahti E, Vuopala S, Kauppila A, Blanco G, Ruokonen A, Laatikainen T. Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen. Gynecol Oncol 1994; 55: 410-4.
55. Gill BL, Simpson JF, Somlo G, McGonigle KF, Wilczynski SP. Effects of tamoxifen on the cytology of the uterine cervix in breast cancer patients. Diagn Cytopathol 1998; 19: 417-22.
56. Ferrazzi E, Cartei G, Mattarazzo R, Fiorentino M. Oestrogen-like effect of tamoxifen on vaginal epithelium. BMJ 1977; 1: 1351-2.
57. Boccardo F, Bruzzi P, Rubagotti A, Nicolo GU, Rosso R. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 1981; 38: 281-5.
58. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 1999; 17: 1488-92.
59. Mattsson LA, Cullberg G. Vaginal absorption of two estriol preparations. A comparative study in postmenopausal women. Acta Obstet Gynecol Scand 1983; 62: 393-6.
60. Ganz PA, Coscarelli A, Fred C, Kahn B, Polinsky ML, Petersen L. Breast cancer survivors: psychosocial concerns and quality of life. Breast Cancer Res Treat 1996; 38: 183-99.
61. Granberg S, Wikland M, Karlsson B, Norstrom A, Friberg LG. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991; 164: 47-52.
62. Goldstein SR, Nachtigall M, Snyder JR, Nachtigall L. Endometrial assessment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding. Am J Obstet Gynecol 1990; 163: 119-23.
63. Cohen I, Rosen DJ, Shapira J, et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 1994; 52: 185-90.
64. Fong K, Causer P, Atri M, Lytwyn A, Kung R. Transvaginal US and hysterosonography in postmenopausal women with breast cancer receiving tamoxifen: correlation with hysteroscopy and pathologic study. Radiographics 2003; 23: 137-50; discussion 151-5.
65. Levine D, Gosink BB, Johnson LA. Change in endometrial thickness in postmenopausal women undergoing hormone replacement therapy. Radiology 1995; 197: 603-8.
66. Gerber B, Krause A, Muller H, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000; 18: 3464-70.
67. Franchi M, Ghezzi F, Donadello N, Zanaboni F, Beretta P, Bolis P. Endometrial thickness in tamoxifen-treated patients: an independent predictor of endometrial disease. Obstet Gynecol 1999; 93: 1004-8.
68. Cohen I, Rosen DJ, Tepper R, et al. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 1993; 12: 275-80.
69. Hulka CA, Hall DA. Endometrial abnormalities associated with tamoxifen therapy for breast cancer: sonographic and pathologic correlation. AJR Am J Roentgenol 1993; 160: 809-12.
70. Cecchini S, Ciatto S, Bonardi R, et al. Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen. Gynecol Oncol 1996; 60: 409-11.
71. Atri M, Nazarnia S, Aldis AE, Reinhold C, Bret PM, Kintzen G. Transvaginal US appearance of endometrial abnormalities. Radiographics 1994; 14: 483-92.
72. Hann LE, Giess CS, Bach AM, Tao Y, Baum HJ, Barakat RR. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. AJR Am J Roentgenol 1997; 168: 657-61.
73. Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P, Dixon JM. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999; 17: 2050-4.
74. Mourits MJ, Van der Zee AG, Willemse PH, Ten Hoor KA, Hollema H, De Vries EG. Discrepancy between ultrasonography and hysteroscopy and histology of endometriurn in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol 1999; 73: 21-6.
75. Wolman I, Jaffa AJ, Hartoov J, Bar-Am A, David MP. Sensitivity and specificity of sonohysterography for the evaluation of the uterine cavity in perimenopausal patients. J Ultrasound Med 1996; 15: 285-8.
76. Dubinsky TJ, Parvey HR, Maklad N. The role of transvaginal sonography and endometrial biopsy in the evaluation of periand postmenopausal bleeding. AJR Am J Roentgenol 1997; 169: 145-9.
77. Langer RD, Pierce JJ, O'Hanlan KA, et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. N Engl J Med 1997; 337: 1792-8.
78. Shipley 3rd CF, Simmons CL, Nelson GH. Comparison of transvaginal sonography with endometrial biopsy in asymptomatic postmenopausal women. J Ultrasound Med 1994; 13: 99-104.
79. Lev-Toaff AS. Sonohysterography: evaluation of endometrial and myometrial abnormalities. Semin Roentgenol 1996; 31: 288-98.
80. Cullinan JA, Fleischer AC, Kepple DM, Arnold AL. Sonohysterography: a technique for endometrial evaluation. Radiographics 1995; 15: 501-14; discussion 515-6.
81. Bourne TH, Lawton F, Leather A, Granberg S, Campbell S, Collins WP. Use of intracavity saline instillation and transvaginal ultrasonography to detect tamoxifen-associated endometrial polyps. Ultrasound Obstet Gynecol 1994; 4: 73-5.
82. Tepper R, Beyth Y, Altaras MM, et al. Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Gynecol Oncol 1997; 64: 386-91.
83. Hann LE, Kim CM, Gonen M, Barakat R, Choi PH, Bach AM. Sonohysterography compared with endometrial biopsy for evaluation of the endometrium in tamoxifen-treated women. J Ultrasound Med 2003; 22: 1173-9.
84. Fong K, Kung R, Lytwyn A, et al. Endometrial evaluation with transvaginal US and hysterosonography in asymptomatic postmenopausal women with breast cancer receiving tamoxifen. Radiology 2001; 220: 765-73.
85. Laifer-Narin SL, Ragavendra N, Lu DS, Sayre J, Perrella RR, Grant EG. Transvaginal saline hysterosonography: characteristics distinguishing malignant and various benign conditions. AJR Am J Roentgenol 1999; 172: 1513-20.
86. Develioglu OH, Omak M, Bilgin T, Esmer A, Tufekci M. The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow. Gynecol Oncol 2004; 93: 328-35.
87. Sladkevicius P, Valentin L, Marsal K. Endometrial thickness and Doppler velocimetry of the uterine arteries as discriminators of endometrial status in women with postmenopausal bleeding: a comparative study. Am J Obstet Gynecol 1994; 171: 722-8.
88. Achiron R, Lipitz S, Sivan E, et al. Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study. Ultrasound Obstet Gynecol 1995; 6: 116-20.
89. Ascher SM JJ, Zeman RK, Patt RH. Uterine changes in women receiving tamoxifen therapy: prospective comparison of MR imaging and transvaginal sonography with pathologic correlation. Radiology 1995; 197 (P): 353-354 (abstract).
90. Ascher SM, Johnson JC, Barnes WA, Bae CJ, Patt RH, Zeman RK. MR imaging appearance of the uterus in Postmenopausal women receiving tamoxifen therapy for breast cancer: histopathologic correlation. Radiology 1996; 200: 105-10.
91. Silva A, Ascher S, Reinhold C. Magnetic resonance imaging versus ultrasound in the assessment of benign uterine lesions. In: Lang EK, editor. Radiology of the female pelvic organs. Berlin, Heidelberg, New York: Springer-Verlag; 1998, p. 43-67.
92. Hricak H, Stern JL, Fisher MR, Shapeero LG, Winkler ML, Lacey CG. Endometrial carcinoma staging by MR imaging. Radiology 1987; 162: 297-305.
93. Hricak H, Hamm B, Semelka RC, et al. Carcinoma of the uterus: use of gadopentetate dimeglumine in MR imaging. Radiology 1991; 181: 95-106.
94. Ito K, Matsumoto T, Nakada T, Nakanishi T, Fujita N, Yamashita H. Assessing myometrial invasion by endometrial carcinoma with dynamic MRI. J Comput Assist Tomogr 1994; 18: 77-86.
95. DelMaschio A, Vanzulli A, Sironi S, et al. Estimating the depth of myometrial involvement by endometrial carcinoma: efficacy of transvaginal sonography vs MR imaging. AJR Am J Roentgenol 1993; 160: 533-8.